中药新药申请生产药学审评中的常见问题及建议  

Common questions and suggestions of evaluation for NDA of TCM

作　　者：马秀璟[1] 张永文[1] 阳长明[1] 

机构地区：[1]国家食品药品监督管理总局药品审评中心,北京100038

出　　处：《中国中药杂志》2014年第17期3395-3398,共4页China Journal of Chinese Materia Medica

摘　　要：依据我国现行《药品注册管理办法》(局令第28号),中药新药的注册申请分为申请临床试验和申请生产(包括新药证书)。从申请临床到获准上市,大约经历10年之久,且申请生产的成功率较低,目前存在问题较多。从药学审评看,主要存在合规性和技术性2个方面的问题。主要表现为不经国家主管部门批准的擅自变更,如:临床试验用样品的制备工艺与批准的工艺有较大改变。技术性问题主要有申报资料不全或申报资料不符合技术审评要求,如:不提供生产工艺验证资料、临床试验用样品的制备工艺及现场检查用生产工艺资料,或提供的资料不符合技术要求等。该文对常见问题进行了总结并提出建议,提醒申请人关注,以便及时发现问题,规避风险,提高注册申请的质量和效率。According to the existing Provisions for Drug Registration （ SFDA Order No. 28）, applications for new drugs of traditional Chinese medicine are divided into two parts ： the applications for drug clinical trial and for drug production （ including new drug certificate）. It will last for about 10 years from the application for drug clinical trial to get approving, and it also remains many problems and the low probability to succeed. From the sight of pharmaceutical review, there are mainly two aspects of regulatory compliance and technical issues, mainly for changes without approval of the competent authorities of the country. For example, sample preparation and approval of clinical trial process are significant changes. Technical problems are reporting incomplete data or information submitted does not comply with the technical requirements for review, such as： production process validation does not provide information, the preparation of samples for clinical trials and field inspection, production information, or the information provided does not meet the technical requirements. This paper summarizes the frequently asked questions and to make recommendations to advise applicants concerned, timely detection of problems, avoid risk, improving the quality and efficiency of the application for registration.

关 键 词：中药申请生产 药学审评 问题及建议 

分 类 号：R288[医药卫生—中药学]